Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Chemotherapeutics for Triple-Negative Breast Cancer

February 25th 2015

Standard Therapies for Triple-Negative Breast Cancer

February 25th 2015

Managing Brain Metastases in Breast Cancer

February 25th 2015

Role of T-DM1 in HER2-Positive Breast Cancer

February 25th 2015

Pertuzumab in HER2-Positive Metastatic Breast Cancer

February 25th 2015

BOLERO-2: Everolimus Plus Exemestane in Resistant MBC

February 25th 2015

Role of Bevacizumab in Breast Cancer

February 25th 2015

Endocrine Therapy Resistance in Breast Cancer

February 25th 2015

CDK4/6 Inhibition in Metastatic Breast Cancer

February 25th 2015

Treating ER-Positive De Novo Metastatic Breast Cancer

February 25th 2015

Genetic Tests Offer New Tool for Tumor Assessment

February 25th 2015

Pathology, Oncology Collaboration in Breast Cancer

February 25th 2015

Predicting Risk of Recurrence in Breast Cancer

February 25th 2015

Reviewing Key Genomic Assays in Breast Cancer

February 25th 2015

Pathologist's Role in Genetic Testing for Breast Cancer

February 25th 2015

Role of Genetic Testing in Breast Cancer

February 25th 2015

Introduction: Impact of Molecular Subtyping in Breast Cancer

February 25th 2015

Dr. Sotomayor on Precision Medicine for the Prevention of Cancer

February 23rd 2015

Eduardo Sotomayor, MD, the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center, discusses the future of personalized medicine in lymphoma.

Molecular Analysis Should Guide Treatment Individualization in AML

February 23rd 2015

Cytogenetic and molecular data are becoming increasingly important in the individualization of treatment for patients of acute myeloid leukemia, according to a presentation by Stefan Faderl, MD, at the 2015 International Congress on Hematologic Malignancies.

First Direct-to-Consumer Genetic Test Gains FDA Approval

February 20th 2015

The FDA has approved its first-ever direct-to-consumer genetic test for the detection of a gene variant that could be associated with Bloom syndrome, a rare inherited disorder associated with a higher risk of developing cancer and other health concerns.